New vaccines for yellow fever and rabies enter first human tests

NCT ID NCT06998004

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested two new vaccines—one for yellow fever and one for rabies—in 112 healthy adults aged 18 to 40. The main goal was to check safety and see how well the vaccines trigger an immune response. Participants received different doses or a placebo to help find the best balance of safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AVX70120 (yellow fever vaccine) and AVX70481 (rabies vaccine)
What this could lead to
If successful, these vaccines could provide new options to prevent yellow fever and rabies, potentially improving protection for travelers and people in affected regions.
What could go wrong
This is a very early Phase 1 trial with only 112 healthy adults. The vaccines may not trigger a strong enough immune response or could have unexpected side effects. Much more testing is needed before they could be widely used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

112 people

The number who actually took part.

Started

Jun 2024

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female between, and including, 18 and 40 years of age on the day of the Screening Visit * Healthy individual, as established by the Investigator * Able to read and understand the informed consent form, and written informed consent obtained from the participant * Participants who, in the opinion of the Investigator, can and will comply with the requirements of the protocol Exclusion Criteria: * Body Mass Index \<18.0 or \>32.0 kg/m2 * Use of any investigational or non-registered product other than the study intervention within 1 month preceding study vaccination, or planned use during the study period * Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or non-registered product * Administration / planned administration of any vaccine not foreseen by the study protocol within 1 month preceding study vaccination and up to Day 31 * Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months preceding study vaccination, or planned chronic administration at any time during the study period * Planned administration of long-acting immune-modifying drugs at any time during the study period * Administration of immunoglobulins and / or any blood or blood-derived products within 3 months preceding study vaccination, or planned administration during the study period * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history, family history or physical examination * History of or current autoimmune disease * Personal or family history of thymic pathology * History of any neurological disorders or seizures * History of any reaction or hypersensitivity likely to be exacerbated by any component of the investigational vaccines * Malignancies or lymphoproliferative disorders within previous 5 years * Moderate or severe acute disease in the opinion of the Investigator, and / or fever at the time of study intervention * Alcohol, prescription drug, or substance (ab)use that, in the opinion of the Investigator, might interfere with the study conduct or completion * Pregnant or lactating woman * Woman of childbearing potential who is not utilising a highly effective birth control method for at least 1 month preceding study vaccination, or planning to discontinue highly effective birth control methods during the study period. * Participants employed by the Sponsor, by the vendors working on behalf of the Sponsor, by the Investigator or the study site, or close relatives of research staff working on this study * Medical condition or use of medication(s) that can increase the risk of bleeding or haematoma * Any other condition or finding that the Investigator judges may interfere with study procedures or study results Note: other protocol-defined inclusion / exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rabies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre for the Evaluation of Vaccination (CEV)

    Antwerp, Belgium

  • University Hospital Ghent - Centrum voor Vaccinologie (CEVAC)

    Ghent, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.